contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


astrazeneca-invests-dollar35-billion-in-randd-and-manufacturing-in-the-united-states

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

AstraZeneca is a global pharmaceutical company focused on the research, development and marketing of prescription medicines, primarily for the treatment of diseases in the therapeutic areas of respiratory, cardiovascular/metabolic and cancer. In addition to its core business, the company also has a focus on the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in all global regions and is headquartered in Cambridge, UK.

AstraZeneca

AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company's research and manufacturing footprint by the end of 2026. This includes ...

<div class="abstract">AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company's research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the growth of the US economy.</div>AstraZeneca's expanding footprint in the US includes, among others:<ul><li>A state-of-the-art R&amp;D centre in Kendall Square, Cambridge, Massachusetts</li><li>A next generation manufacturing facility for biologics in Maryland</li><li>Cell therapy manufacturing capacity on the West and East Coasts</li><li>Specialty manufacturing in Texas</li></ul>Pascal Soriot, Chief Executive Officer, AstraZeneca said: "Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States. By expanding our R&amp;D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation."Delivering growth: Ambition 2030These US investments are the first of a series of important steps to help deliver AstraZeneca's ambition to achieve $80 billion in Total Revenue by 2030 as set out in May this year&nbsp;(<a href="https://www.astrazeneca.com/investor-relations/astrazeneca-investor-day.html">https://www.astrazeneca.com/investor-relations/astrazeneca-investor-day.html</a>). A key element of our strategy is accelerating the Company's development in the United States. The US is AstraZeneca's largest market, generating 44% of its Total Revenue.[1]AstraZeneca in the USAstraZeneca has approximately 17,800 employees working across 17 R&amp;D, manufacturing and commercial sites spanning 12 states.AstraZeneca&nbsp;(<a href="https://www.astrazeneca.com/">https://www.astrazeneca.com/</a>)AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal &amp; Metabolism, and Respiratory &amp; Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit&nbsp;astrazeneca.com&nbsp;(<a href="http://www.astrazeneca.com/">http://www.astrazeneca.com/</a>)&nbsp;and follow the Company on social media&nbsp;@AstraZeneca&nbsp;(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&amp;_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)Contacts For details on how to contact the Investor Relations Team, please click&nbsp;here&nbsp;(<a href="https://www.astrazeneca.com/investor-relations.html#Contacts">https://www.astrazeneca.com/investor-relations.html#Contacts</a>). For Media contacts, click&nbsp;here&nbsp;(<a href="https://www.astrazeneca.com/media-centre/contacts.html">https://www.astrazeneca.com/media-centre/contacts.html</a>).References1. As at Q3 2024 noted in AstraZeneca Q3 Financial Results. Available at:&nbsp; <a href="https://www.astrazeneca.com/media-centre/press-releases/2024/9m-and-q3-2024-results.html">https://www.astrazeneca.com/media-centre/press-releases/2024/9m-and-q3-2024-results.html</a>. Accessed November 2024.

AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States

Mandatum

Fortum

Nordea Bank

Verkkokauppa.com

Arvo Sijoitusosuuskunta

Terveystalo

Pihlajalinna

Metsä Board

Oriola

Fiskars

Titanium

Stora Enso

UPM-Kymmene

Osinkonäkymät 2026: pörssin osinkotuotto laskee

Namaste, EU-Intia-kauppasopimus!

Euroopan pankkisektori: tasealennuksesta kärkisektoriksi

Paniikkia ja maniaa pörssissä samaan aikaan

Työkyvyn kallis hinta – Ekonomisti fundeeraa